Pharmacology animations
Articles filed under Pharmacology animations.
Animation explaining mechanism of action of glucocorticoids and comparative glucocorticoids potencies table.
Mechanism of action of adrenocorticosteroids – from: Bertram G. Katzung, Basic & Clinical Pharmacology (Mc Graw-Hill Medical, 2007) – “Most of the known effects of the glucocorticoids are mediated by widely distributed glucocorticoid receptors. These proteins are members of the superfamily of nuclear receptors that includes steroid, sterol (vitamin D), thyroid, retinoic acid, and many
Alpha 1 adrenergic receptors antagonists (blockers): mechanism of action animation
Additional information about alpha 1 blocking drugs. Source: Bertram G. Katzung, Basic & Clinical Pharmacology (Mc Graw-Hill Medical, 2007) ” Phentolamine, an imidazoline derivative, is a potent competitive antagonist at both alpha 1 and alpha 2 receptors . Phentolamine causes a reduction in peripheral resistance through blockade of alpha 1 receptors and possibly alpha 2
Epinephrine (adrenaline) mechanism of action: animation showing the signal transduction process
Drugs related to this animation Adrenoceptor-Activating & Other Sympathomimetic Drugs:Dobutamine, Ephedrine, Epinephrine, Hydroxyamphetamine, Isoproterenol, Methylphenidate, Naphazoline, Norepinephrine. Source of animation: Lodish, et al., Molecular Cell Biology, Fifth Edition, W. H. Freeman & Co.Developed by Sumanas, Inc.
Estradiol receptor signal transduction: 3-D video animations explaining its mechanism of action.
Two excelent 3D animations about the mechanism of action of estradiol in the activation of estradiol receptor. Additional information from Wikipedia article on estrogen receptor: “There are two types of estrogen receptor, ER is a member of the nuclear hormone family of intracellular receptors which is activated by the hormone 17β-estradiol[1] (estrogen), while the estrogen
Pharmacodynamics animation: full agonists, partial agonists, inverse agonists, competitive antagonists and irreversible antagonists.
First, some pharmacodynamic definitions related to the animation: Full Agonists: Compounds that are able to elicit a maximal response following receptor occupation and activation. Partial Agonists: Compounds that can activate receptors but are unable to elicit the maximal response of the receptor system. Inverse agonist: an agent which binds to the same receptor binding-site as
Drugs acting on the autonomic nervous system: animation showing their mechanism of action
The following is a list of drugs related to the animation: Adrenoceptor-Activating & Other Sympathomimetic Drugs Dobutamine, Ephedrine, Epinephrine, Hydroxyamphetamine, Isoproterenol, Methylphenidate, Naphazoline, Norepinephrine. Adrenoceptor Antagonist Drugs Acebutolol, Atenolol, Betaxolol, Bisoprolol, Carteolol, Carvedilo,l Carvedilol, Esmolol, Labetalol, Metoprolol, Nadolol, Pindolol, Propranolol, Sotalol, Timolol. Cholinoceptor-Activating (Acetylcholine receptor stimulants) Acetylcholine, Bethanechol, Carbachol, Cevimeline, Pilocarpine. Cholinoceptor-Blocking Drugs (Cholinoceptor antagonists)
Anticholinergics mechanism of action in bronchodilation
Some additional information from Goodman & Gilman’s Anticholinergic Agents With the advent of inhaled beta adrenergic agonists, use of anticholinergic agents declined. Renewed interest in anticholinergic agents paralleled the realization that parasympathetic pathways are important in bronchospasm in some asthmatics and the availability of ipratropium bromide (ATROVENT), a quaternary muscarinic receptor antagonist that has better
Beta lactams antibiotics (penicillins and cephalosporins) mechanism of action: videos and animations
Mechanism of action of the beta lactam antibiotics (penicillins and cephalosporins) The beta-lactam antibiotics can kill susceptible bacteria. Although knowledge of the mechanism of this action is incomplete, numerous researchers have supplied information that allows understanding of the basic phenomenon (seeGhuysen, 1991; Bayles, 2000). The cell walls of bacteria are essential for their normal growth
Mechanisms of antimicrobial resistance: video animations produced by FDA
The following video explains the mechanisms that bacteria use to develop antibiotic resistance: Mechanisms of Antimicrobial Resistance Mutation Destruction or Inactivation Efflux ( 1:00) Genetic Transfer Conjugation Transformation Transduction
Cisplatin mechanism of action: 3-D video animation
Mechanism of Action. Cisplatin, carboplatin, and oxaliplatin enter cells by diffusion, and by an active Cu2+ transporter (Kruh, 2003). Inside the cell, the chloride atoms of cisplatin may be displaced and the compound may be inactivated directly by reaction with nucleophiles such as thiols. Chloride is replaced by water, yielding a positively charged molecule. In
G protein-coupled receptors: 3-D video and text
G protein-coupled receptors are the most abundant class of receptors in the human body. These receptors are exposed at the extracellular surface of the cell membrane, traverse the membrane, and possess intracellular regions that activate a unique class of signaling molecules called G proteins. (G proteins are so named because they bind the guanine nucleotides
Animation: insulin secretion and sulfonylureas mechanism of action
Animation that depicts how sulfonylureas enhance insulin secretion by binding to specific beta cell receptors. Download available
Statins: mechanism of action and side effects
An overview on the mechanism of action of statins: HMG CoA reductase inhibitors,or statins are widely prescribed drugs. They are indicated for the treatment of hipercholesterolemia, a condition that increases cardiovascular risk. Currently, the drugs of this group that are available are: Atorvastatin Fluvastatin Lovastatin Mevastatin Pitavastatin Pravastatin Rosuvastatin Simvastatin Mechanism of action. Animation explained
Imatinib (Gleevec) pharmacology: mechanism of action and therapeutic considerations
Imatinib mesylate is a small-molecule tyrosine kinase inhibitor that was initially developed as a 2-phenylaminopyrimidine derivative specific for PDGFR. Imatinib was subsequently found to be a potent inhibitor of ABL kinases, including the BCR-ABL fusion protein generated as a result of the t(9;22) chromosomal translocation (Philadelphia chromosome) found in chronic myelogenous leukemia (CML), and was